Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00993655
Other study ID # OV21
Secondary ID CAN-NCIC-OV21UCL
Status Completed
Phase Phase 2
First received
Last updated
Start date March 3, 2010
Est. completion date July 11, 2016

Study information

Verified date March 2020
Source Canadian Cancer Trials Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating patients with ovarian epithelial cancer, primary peritoneal cancer, and fallopian tube cancer. PURPOSE: This randomized phase II trial is comparing the side effects of three combination chemotherapy regimens and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.


Description:

OBJECTIVES: Primary - To compare the efficacy of the selected IP chemotherapy regimen (Arm 3: IV paclitaxel and IP carboplatin plus day 8 IP paclitaxel) versus IV carboplatin plus paclitaxel (Arm 1) in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy. Nine month progressive rate post randomization is the primary endpoint for assessment of efficacy. Secondary - To compare IP plus IV chemotherapy versus IV carboplatin plus paclitaxel with respect to progression free survival and overall survival. OUTLINE: This is a multicenter study. Patients are stratified according to cooperative group, residual disease (observable [e.g., macroscopic] disease that is evident at end of delayed primary debulking surgery vs no evidence of observable disease at end of delayed primary debulking surgery), reason for delayed primary debulking surgery at initial diagnosis (nonresectable disease vs other reasons), and timing of intraperitoneal catheter insertion (intra-operative catheter insertion vs post-operative insertion). - Phase II: Patients are randomized to 1 of 3 treatment groups. - ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles - ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-Feb-03) - ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles. Patients also receive carboplatin IP on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. - Expanded Phase II: Patients are randomized to 1 of 2 treatment groups. - Arm I: Patients receive paclitaxel and carboplatin as in phase II, arm I. - Arm III: Patients receive paclitaxel and cisplatin as in phase II, arm II or paclitaxel and carboplatin as in phase II, arm III. Patients complete quality of life questionnaires EORTC QLQ-C30, ovarian cancer module (EORTC QLQ-OV28), and FACT/GOG-Ntx at baseline, on day 1 of courses 2 and 3, at 3, 6 and 12 months after completion of study treatment, and then annually until disease progression, death, or initiation of second-line therapy. After completion of study treatment, patients are followed at 6 weeks, every 3 months for 2 years, every 6 months for 2 years, and then annually until progression, death, or initiation of second-line therapy.


Recruitment information / eligibility

Status Completed
Enrollment 275
Est. completion date July 11, 2016
Est. primary completion date March 10, 2016
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial, primary serous type peritoneal, or fallopian tube carcinoma - Patients with ovarian cancer of the clear cell histology are eligible. Histologic confirmation is preferably by biopsy or limited excision prior to neo-adjuvant treatment. If the diagnosis prior to neo-adjuvant chemotherapy is based on cytology, histologic confirmation is required prior to randomization. Histologic confirmation can be obtained at the time of debulking surgery by intra-operative frozen section, thus permitting intra-operative randomization, or by final pathologic review of the resected specimen if randomization is to be performed following debulking surgery. - Initial FIGO stage IIB-III disease - Stage IV disease allowed provided the only criterion for stage IV disease is the presence of a pleural effusion confirmed to be associated with positive cytology for ovarian cancer - Completed = 3 but no more than 4 courses of platinum-based neoadjuvant chemotherapy prior to the first debulking surgery - Meets the following criteria for surgical treatment prior to randomization: - Initial Diagnosis: No debulking surgery was attempted or completed. - The patient's first cytoreductive (debulking) surgery must be after neoadjuvant chemotherapy (Delayed Primary Debulking). The delayed primary debulking surgery must be completed no more than 4 weeks after commencing administering of the last cycle of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization. - Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy and any additional procedures required to achieve maximal cytoreduction with residual disease of 1 cm or less as assessed by the surgeon at the end of surgery. - Delayed primary debulking surgery must be completed no more than 4 weeks after the last course of neoadjuvant chemotherapy and must be completed no more than 6 weeks prior to randomization - Surgery will include total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and any additional procedures required to achieve maximal cytoreduction with residual disease of = 1 cm as assessed by the surgeon at the end of surgery - No borderline ovarian tumors (i.e., tumors of low malignant potential) alone - No mucinous tumor PATIENT CHARACTERISTICS: - ECOG performance status 0-2 - Life expectancy = 12 weeks - Granulocyte count = 1.5 x 10^9/L - Platelet count = 100 x 10^9/L - Serum creatinine = upper limit of normal (ULN) OR > ULN to = 1.25 ULN provided measured creatinine clearance is > 60 mL/min - Serum bilirubin normal - AST/ALT = 2.5 times ULN - Fertile patients must use effective contraception - Able (i.e., sufficiently fluent) and willing to complete the quality of life questionnaires - Accessible for treatment and follow-up - No history of other malignancy, except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other solid tumors curatively treated with no evidence of disease for = 5 years - No uncontrolled atrial or ventricular arrhythmias including second or third degree heart block unless managed with implanted pacemaker - Patients with a history of first degree heart block are eligible - No documented myocardial infarction within the past 6 months preceding randomization (pretreatment ECG evidence only of infarct will not exclude patients) - No diagnosis of bowel obstruction - No serious illness or medical condition which would not permit the patient to be managed according to protocol including, but not limited to, any of the following: - Prior allergic reactions to drugs containing cremophor or to compounds chemically related to cisplatin, paclitaxel, or carboplatin - Symptomatic congestive heart failure within the past 6 months or other conditions which would lead to a contraindication of a high-volume saline diuresis - History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent - Active uncontrolled infection - Persistent peripheral neuropathy or hearing loss = grade 2 resulting from prior therapy - Extensive intraperitoneal adhesion intra- or post-operatively which would impede intraperitoneal treatment delivery PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No prior therapy for ovarian cancer, except for neoadjuvant platinum-based chemotherapy and surgery - No concurrent intraperitoneal adhesion barriers - No other concurrent anticancer treatment, including cytotoxic agents, biological response modifiers, immunotherapy, anticancer hormone therapy, or investigational drug therapy - No other concurrent experimental drugs or anticancer therapy

Study Design


Intervention

Drug:
carboplatin
Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
cisplatin
Cisplatin 75 mg/m2 intraperitoneal day 1
paclitaxel
Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles

Locations

Country Name City State
Canada Tom Baker Cancer Centre Calgary Alberta
Canada Cross Cancer Institute Edmonton Alberta
Canada QEII Health Sciences Centre Halifax Nova Scotia
Canada BCCA - Cancer Centre for the Southern Interior Kelowna British Columbia
Canada Cancer Centre of Southeastern Ontario at Kingston Kingston Ontario
Canada London Regional Cancer Program London Ontario
Canada CHUM - Hopital Notre-Dame Montreal Quebec
Canada Hopital Maisonneuve-Rosemont Montreal Quebec
Canada McGill University - Dept. Oncology Montreal Quebec
Canada Ottawa Hospital Research Institute Ottawa Ontario
Canada CHUQ-Pavillon Hotel-Dieu de Quebec Quebec City Quebec
Canada Regional Health Authority B, Zone 2 Saint John New Brunswick
Canada Centre hospitalier universitaire de Sherbrooke Sherbrooke Quebec
Canada Dr. H. Bliss Murphy Cancer Centre St. John's Newfoundland and Labrador
Canada BCCA - Fraser Valley Cancer Centre Surrey British Columbia
Canada Thunder Bay Regional Health Science Centre Thunder Bay Ontario
Canada Univ. Health Network-Princess Margaret Hospital Toronto Ontario
Canada BCCA - Vancouver Cancer Centre Vancouver British Columbia
Canada CancerCare Manitoba Winnipeg Manitoba
Spain Hospital Fundacion Alcorcon Alcorcon Madrid
Spain Corporacio Sanitaria Clinic Barcelona
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital Vall d'Hebron Barcelona
Spain Instituto Catalan de Oncologia - L'Hospitalet Hospitalet de Llobregat Barcelona
Spain Centro Oncologico MD Anderson - Madrid Madrid
Spain Hospital Clinico San Carlos Madrid
Spain Hospital Gregorio Maranon Madrid
Spain Fundacion Instituto Valenciano de Oncologia Valencia
Spain Hospital Clinico Universitario de Valencia Valencia
United Kingdom The Western General Hospital - Edinburgh Edinburgh
United Kingdom St. James University Hospital - Leeds Leeds
United Kingdom Liverpool Women's Hospital - Liverpool Liverpool
United Kingdom St. Bartholomew's Hospital - London London
United Kingdom St. George's Hospital - London London Tooting
United Kingdom The Hammersmith Hospital - London London
United Kingdom The Royal Marsden Hospital - London London
United Kingdom University College London Hospital - London London
United Kingdom St Marys Hospital - Manchester Manchester
United Kingdom The Christie Hospital - Manchester Manchester Withington
United Kingdom Mount Vernon Hospital - Middlesex Middlesex Northwood
United Kingdom The Churchill Hospital - Oxford Oxford
United Kingdom The Derriford Hospital - Plymouth Plymouth
United Kingdom Wexham Park Hospital Slough Wexham
United Kingdom The Clatterbridge Center for Oncology - Liverpool Wirral Bebington
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Women and Infants Hospital of Rhode Island Providence Rhode Island
United States Univ of Utah (Huntsman Cancer Institute) Salt Lake City Utah
United States CoxHealth Springfield Missouri
United States Mercy-Springfield Springfield Missouri
United States Northwest CCOP - Multicare Health System Tacoma Washington

Sponsors (5)

Lead Sponsor Collaborator
Canadian Cancer Trials Group Cancer Research UK, Grupo Español de Investigación en Cáncer de Ovario, National Cancer Institute (NCI), SWOG Cancer Research Network

Countries where clinical trial is conducted

United States,  Canada,  Spain,  United Kingdom, 

References & Publications (1)

Provencher DM, Gallagher CJ, Parulekar WR, Ledermann JA, Armstrong DK, Brundage M, Gourley C, Romero I, Gonzalez-Martin A, Feeney M, Bessette P, Hall M, Weberpals JI, Hall G, Lau SK, Gauthier P, Fung-Kee-Fung M, Eisenhauer EA, Winch C, Tu D, MacKay HJ. OV — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 9-month Progression Rate Post-randomization It is defined as proportion of patients who had progressed at or before 9 months after randomization, i.e., the time from the randomization to the date when the first observation of disease progression (earliest of the date when the first CA 125 meets progression definition and the date of first objective relapse or progression, defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, recorded) has been documented or when death due to any cause has been observed was less than or equal to 9 months. 9 months
Secondary Progression Free Survival Time from the day of randomization until the time when first observation of disease progression (earliest of the dates of first CA125 which meets progression definition and first objective relapse or progression defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, has been documented or when death due to any cause has been observed. During the study with median follow-up of 33 months
Secondary Overall Survival Time from the day of randomization to death from any cause. During the study with median follow-up of 33 months
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2